trimetrexate has been researched along with Colonic Neoplasms in 9 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-five samples of fresh malignant cells of patients with acute leukemia (16 with acute myeloblastic leukemia, five with acute lymphoblastic leukemia, and four with chronic myelocytic leukemia in blast crisis) and of two patients with colon carcinoma were exposed for 1 hr to different concentrations of methotrexate (MTX) or trimetrexate (TMQ)." | 7.67 | Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells. ( Bertino, JR; McGuire, JJ; Rodenhuis, S; Sawicki, WL, 1987) |
| "Within three repeated 7-day incubation periods with either methotrexate (MTX) or trimetrexate (TMTX), human colon adenocarcinoma cells (HCT-8) developed high levels of resistance to these drugs, as evidenced by approximately 20- and 50-fold increases, respectively, in the median effective doses." | 3.68 | Rapid development of resistance to antifolates in vitro: possible clinical implication. ( Aschele, C; Bertino, JR; Nicolin, A; Rosso, R; Sobrero, A, 1991) |
| "Twenty-five samples of fresh malignant cells of patients with acute leukemia (16 with acute myeloblastic leukemia, five with acute lymphoblastic leukemia, and four with chronic myelocytic leukemia in blast crisis) and of two patients with colon carcinoma were exposed for 1 hr to different concentrations of methotrexate (MTX) or trimetrexate (TMQ)." | 3.67 | Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells. ( Bertino, JR; McGuire, JJ; Rodenhuis, S; Sawicki, WL, 1987) |
| "Next, human HCT-8 and HCT-116 colon cancer cells retrovirally transduced to express a DHFR-herpes simplex virus 1 thymidine kinase (HSV1 TK) fusion protein and treated with the DHFR inhibitor TMTX exhibited increased levels of the DHFR-HSV1 TK fusion protein and an increase in ganciclovir sensitivity by 250-fold." | 1.31 | Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. ( Akhurst, T; Balatoni, J; Banerjee, D; Bertino, JR; Blasberg, R; Bornmann, W; Doubrovin, M; Finn, R; Fong, Y; Gelovani Tjuvajev, J; Iwamoto, M; Larson, S; Malhotra, S; Mayer-Kuckuk, P, 2002) |
| "MAWI colonic cancer cells respond to sequential treatment in vitro with carboxypeptidase G2 and trimetrexate by a delay in cell growth as measured by cell numbers, but an increase in incorporation of 75-Se-selenomethionine per cell." | 1.28 | Carboxypeptidase G2 and trimetrexate cause growth delay of human colonic cancer cells in vitro. ( Bagshawe, KD; Bradshaw, T; Mellor, B; Melton, RG; Pedley, RB; Searle, F; Sherwood, RF, 1990) |
| "Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients." | 1.28 | Hypersensitivity reactions to trimetrexate. ( Brown, TD; Costanza, ME; Grem, JL; King, SA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanke, CD | 1 |
| Kasimis, B | 1 |
| Schein, P | 1 |
| Capizzi, R | 1 |
| Kurman, M | 1 |
| Faessel, HM | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Greco, WR | 1 |
| Mayer-Kuckuk, P | 1 |
| Banerjee, D | 1 |
| Malhotra, S | 1 |
| Doubrovin, M | 1 |
| Iwamoto, M | 1 |
| Akhurst, T | 1 |
| Balatoni, J | 1 |
| Bornmann, W | 1 |
| Finn, R | 1 |
| Larson, S | 1 |
| Fong, Y | 1 |
| Gelovani Tjuvajev, J | 1 |
| Blasberg, R | 1 |
| Bertino, JR | 5 |
| Sobrero, A | 2 |
| Aschele, C | 1 |
| Rosso, R | 2 |
| Nicolin, A | 2 |
| Searle, F | 1 |
| Bagshawe, KD | 1 |
| Pedley, RB | 1 |
| Bradshaw, T | 1 |
| Melton, RG | 1 |
| Sherwood, RF | 1 |
| Mellor, B | 1 |
| Grem, JL | 1 |
| King, SA | 1 |
| Costanza, ME | 1 |
| Brown, TD | 1 |
| Romanini, A | 1 |
| Russello, O | 1 |
| Sobrero, AF | 1 |
| Rodenhuis, S | 1 |
| McGuire, JJ | 1 |
| Sawicki, WL | 1 |
1 trial available for trimetrexate and Colonic Neoplasms
| Article | Year |
|---|---|
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic N | 1997 |
8 other studies available for trimetrexate and Colonic Neoplasms
| Article | Year |
|---|---|
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; D | 1999 |
Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression.
Topics: Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Induction; Folic Acid; Folic Ac | 2002 |
Rapid development of resistance to antifolates in vitro: possible clinical implication.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; | 1991 |
Carboxypeptidase G2 and trimetrexate cause growth delay of human colonic cancer cells in vitro.
Topics: Animals; Antineoplastic Agents; Carboxypeptidases; Cell Division; Colonic Neoplasms; Culture Media; | 1990 |
Hypersensitivity reactions to trimetrexate.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Hyper | 1990 |
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Un | 1989 |
Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.
Topics: Adenocarcinoma; Animals; Cattle; Cell Adhesion; Colonic Neoplasms; Colony-Forming Units Assay; Cultu | 1986 |
Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.
Topics: Adenocarcinoma; Colonic Neoplasms; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; | 1987 |